Literature DB >> 26809765

Intraoperative Anemia and Single Red Blood Cell Transfusion During Cardiac Surgery: An Assessment of Postoperative Outcome Including Patients Refusing Blood Transfusion.

Esther K Hogervorst1, Peter M J Rosseel2, Leo M G van de Watering1, Anneke Brand1, M Bentala3, Johanna G van der Bom4, Nardo J M van der Meer5.   

Abstract

OBJECTIVES: Increasing evidence suggests benefits from restrictive red blood cell transfusion (RBC) thresholds in major surgery and critically ill patients. However, these benefits are not obvious in cardiac surgery patients with intraoperative anemia. The authors examined the association between uncorrected hemoglobin (Hb) levels and selected postoperative outcomes as well as the effects of RBCs.
DESIGN: Cohort study with prospectively collected data from a cardiac surgery registry.
SETTING: A major cardiac surgical hospital within the Netherlands, which is also a referral center for Jehovah's Witnesses. PARTICIPANTS: Patients (23,860) undergoing cardiac surgery between 1997 and 2013.
INTERVENTIONS: Comparisons were done in patients with intraoperative nadir Hb<8 g/dL and/or an Hb decrease ≥ 50%. Comparison (A) between Jehovah's Witnesses (Witnesses) and matched non-Jehovah's Witnesses (non-Witnesses) transfused with 1 unit of RBC, and comparison (B) between patients given 1 unit of RBC intraoperatively versus matched non-transfused patients.
MEASUREMENTS AND MAIN RESULTS: Postoperative outcomes were myocardial infarction, renal replacement therapy, stroke, and death. With propensity matching, the authors optimized exchangeability of the compared groups. Adverse outcomes increased with a decreasing Hb both among Witnesses and among non-Witnesses. The incidence of postoperative complications did not differ between Witnesses and matched non-Witnesses who received RBC (adjusted odds ratio 1.44, 95% confidence interval 0.63-3.29). Similarly, postoperative complications did not differ between patients who received a red cell transfusion and matched patients who did not (adjusted odds ratio 0.94, confidence interval 0.72-1.23).
CONCLUSION: Intraoperative anemia is associated with adverse outcomes after cardiac surgery, and a single RBC transfusion does not seem to influence these outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Jehovah’s Witnesses; anemia; cardiac surgery; postoperative outcomes; red blood cell transfusion

Mesh:

Substances:

Year:  2015        PMID: 26809765     DOI: 10.1053/j.jvca.2015.10.021

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

Review 1.  The Effect of Blood Transfusion on Outcomes in Aortic Surgery.

Authors:  Camilo A Velasquez; Mrinal Singh; Syed Usman Bin Mahmood; Adam J Brownstein; Mohammad A Zafar; Ayman Saeyeldin; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2017-07-27

2.  Risk Factors Associated with Perioperative Myocardial Infarction in Major Open Vascular Surgery.

Authors:  Danielle C Sutzko; Elizabeth A Andraska; Andrea T Obi; Peter K Henke; Nicholas H Osborne
Journal:  Ann Vasc Surg       Date:  2017-09-08       Impact factor: 1.466

3.  Guidelines on transfusion of red blood cells: Prognosis of patients who decline blood transfusions.

Authors:  Dante Mário Langhi; Dimas Tadeu Covas; Jose Francisco Comenalli Marques; Alfredo Mendrone; Eugênia Maria Amorim Ubiali; Gil Cunha De Santis; Gizela Kelmann; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-09-25

4.  Intra-operative red blood cell transfusion and mortality after cardiac surgery.

Authors:  Eline A Vlot; Lisa Verwijmeren; Ewoudt M W van de Garde; Geoffrey T L Kloppenburg; Eric P A van Dongen; Peter G Noordzij
Journal:  BMC Anesthesiol       Date:  2019-05-04       Impact factor: 2.217

Review 5.  Outcomes of cardiac surgery in Jehovah's Witness patients: A review.

Authors:  Aimee-Louise Chambault; Louise J Brown; Sophie Mellor; Amer Harky
Journal:  Perfusion       Date:  2020-12-16       Impact factor: 1.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.